Association, and the Swiss Acad emy of Medical Sciences, was mandated to prepare a review of mammography screening. The two of us, a medical ethicist and a clinical epidemiologist, were mem bers of the expert panel that ap praised the evidence and its impli cations. The other members were a clinical pharmacologist, an onco logic surgeon, a nurse scientist, a lawyer, and a health economist. As we embarked on the project, we were aware of the controversies that have surrounded mammog raphy screening for the past 10 to 15 years. When we reviewed the available evidence and contem plated its implications in detail, however, we became increasingly concerned.
First, we noticed that the ongo ing debate was based on a series of reanalyses of the same, predomi nantly outdated trials. The first trial started more than 50 years ago in New York City and the last trial in 1991 in the United King dom. 1 None of these trials were initiated in the era of modern breastcancer treatment, which has dramatically improved the progno sis of women with breast cancer. Could the modest benefit of mam mography screening in terms of breastcancer mortality that was shown in trials initiated between 1963 and 1991 still be detected in a trial conducted today? Second, we were struck by how nonobvious it was that the bene fits of mammography screening outweighed the harms. The rela tive risk reduction of approximate ly 20% in breastcancer mortality associated with mammography that is currently described by most expert panels 2 came at the price of a considerable diagnostic cas cade, with repeat mammography, subsequent biopsies, and overdiag nosis of breast cancers -can cers that would never have become clinically apparent. The recently published extended followup of the Canadian National Breast Screening Study is likely to pro vide reliable estimates of the extent of overdiagnosis. After 25 years of followup, it found that 106 of 484 screendetected cancers (21.9%) were overdiagnosed. 3 This means that 106 of the 44,925 healthy women in the screening group were diagnosed with and treated for breast cancer unnecessarily, which resulted in needless sur gical interventions, radiotherapy, chemotherapy, or some combina tion of these therapies. In addition, a Cochrane review of 10 trials in volving more than 600,000 women showed there was no evidence suggesting an effect of mammog raphy screening on overall mortal ity. 1 In the best case, the small reduction in breastcancer deaths was attenuated by deaths from other causes. In the worst case, the reduction was canceled out by deaths caused by coexisting condi tions or by the harms of screen ing and associated overtreatment. Did the available evidence, taken together, indicate that mammog raphy screening indeed benefits women?
Third, we were disconcerted by the pronounced discrepancy be tween women's perceptions of the benefits of mammography screen ing and the benefits to be expect ed in reality. The figure shows the numbers of 50yearold women in the United States expected to be alive, to die from breast can cer, or to die from other causes if they are invited to undergo regular mammography every 2 years over a 10year period, as compared with women who do not undergo mammography. The numbers in Panel A are derived from a survey about U.S. women's perceptions, 4 in which 717 of 1003 women (71.5%) said they believed that mammography reduced the risk of breastcancer deaths by at least half, and 723 women (72.1%) thought that at least 80 deaths would be prevented per 1000 women who were invited for screening. The numbers in Panel B reflect the most likely scenarios according to available trials 1-3 : a relative risk reduction of 20% and prevention of 1 breastcancer death. The data for Switzerland, reported in the same study, show similarly overly optimistic expec tations. How can women make an informed decision if they over estimate the benefit of mammog raphy so grossly?
The Swiss Medical Board's re port was made public on February 2, 2014 (www.medicalboard.ch). It acknowledged that systematic mammography screening might prevent about one death attri buted to breast cancer for every 1000 women screened, even though there was no evidence to suggest that overall mortality was affected. At the same time, it em phasized the harm -in particu lar, false positive test results and the risk of overdiagnosis. For every breastcancer death prevented in U.S. women over a 10year course of annual screening beginning at 50 years of age, 490 to 670 women are likely to have a false positive mammogram with repeat exami nation; 70 to 100, an unnecessary biopsy; and 3 to 14, an overdiag nosed breast cancer that would never have become clinically ap parent. 5 The board therefore rec ommended that no new systematic mammography screening pro grams be introduced and that a time limit be placed on existing programs. In addition, it stipulat ed that the quality of all forms of mammography screening should be evaluated and that clear and balanced information should be provided to women regarding the benefits and harms of screening.
The report caused an uproar 
U.S. Women's Perceptions of the Effects of Mammography Screening on Breast-Cancer Mortality as Compared with the Actual Effects.
Panel A shows the views of 50-year-old women in the United States regarding the effect of mammography every 2 years on the 10-year risk of death from breast cancer (at left), as compared with no screening (at right). The areas of the squares are proportional to the numbers of women per 1000 who would be alive (blue), die from breast cancer (orange), or die from other causes (yellow). The numbers were calculated from women's perceived relative and absolute risk reductions for breast-cancer deaths (Domenighetti et al. D r F a r r a h C a n c e r C e n t e r . c o m n engl j med 370;21 nejm.org may 22, 2014 and was emphatically rejected by a number of Swiss cancer experts and organizations, some of which called the conclusions "unethi cal." One of the main arguments used against it was that it contra dicted the global consensus of leading experts in the field -a criticism that made us appreciate our unprejudiced perspective re sulting from our lack of expo sure to past consensusbuilding efforts by specialists in breast cancer screening. Another argu ment was that the report unset tled women, but we wonder how to avoid unsettling women, given the available evidence. The Swiss Medical Board is nongovernmental, and its recom mendations are not legally bind ing. Therefore, it is unclear wheth er the report will have any effect on the policies in our country. Although Switzerland is a small country, there are notable differ ences among re gions, with the French and Italian speaking cantons being much more in favor of screening programs than the Germanspeaking can tons -a finding suggesting that cultural factors need to be taken into account. Eleven of the 26 Swiss cantons have systematic mammography screening pro grams for women 50 years of age or older; two of these pro grams were introduced only last year. One Germanspeaking can ton, Uri, is reconsidering its de cision to start a mammography screening program in light of the board's recommendations. Partici pation in existing programs ranges from 30 to 60% -varia tion that can be partially ex plained by the coexistence of op portunistic screening offered by physicians in private practice. At least three quarters of all Swiss women 50 years of age or older have had a mammogram at least once in their life. Health insurers are required to cover mammog raphy as part of systematic screen ing programs or within the frame work of diagnostic workups of potential breast disease.
It is easy to promote mam mography screening if the major ity of women believe that it pre vents or reduces the risk of getting breast cancer and saves many lives through early detec tion of aggressive tumors. 4 We would be in favor of mammogra phy screening if these beliefs were valid. Unfortunately, they are not, and we believe that women need to be told so. From an ethi cal perspective, a public health program that does not clearly produce more benefits than harms is hard to justify. Providing clear, unbiased information, promoting appropriate care, and preventing overdiagnosis and overtreatment would be a better choice. U nder the Affordable Care Act (ACA), the employer mandate -the requirement that most em ployers offer health insurance to their workers or pay a tax pen alty -was scheduled to go into effect on January 1, 2014. Last summer, however, the Obama administration announced that it was delaying the mandate for a year. The administration has now extended the delay for mid size firms until 2016.
The latest delay has spurred another round of accusations from critics of health care reform that the Obama administration has acted unlawfully in imple menting the ACA. Similar accu sations followed the announce ment of a 1year delay for some insurers of the ACA caps on out ofpocket costs, as well as the de cision to allow people to keep
